B-type natriuretic peptide and acute heart failure: Fluid homeostasis, biomarker and therapeutics

I. Torres-Courchoud, Horng Haur Chen

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Natriuretic peptides are a family of peptides with similar structures, but are genetically distinct with diverse actions in cardiovascular, renal and fluid homeostasis. The family consists of an atrial natriuretic peptide (ANP) and a brain natriuretic peptide (BNP) of myocardial cell origin, a C-type natriuretic peptide (CNP) of endothelial origin, and a urodilatin (Uro) which is processed from a prohormone ANP in the kidney. Nesiritide, a human recombinant BNP, was approved by the Federal Drug Administration (FDA) for the management of acute heart failure (AHF) in 2001. Human recombinant ANP (Carperitide) was approved for the same clinical indication in Japan in 1995, and human recombinant Urodilatin (Ularitide) is currently undergoing phase III clinical trial (TRUE AHF). This review will provide an update on important issues regarding the role of BNP in fluid hemostasis as a biomarker and therapeutics in AHF.

Original languageEnglish (US)
JournalRevista Clinica Espanola
DOIs
StateAccepted/In press - Jan 11 2016

Keywords

  • Brain natriuretic peptide
  • Heart failure
  • Natriuretic peptide
  • Recombinant natriuretic peptides
  • Volume homeostasis

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'B-type natriuretic peptide and acute heart failure: Fluid homeostasis, biomarker and therapeutics'. Together they form a unique fingerprint.

  • Cite this